NovaVision, Inc.

About NovaVision, Inc.

NovaVision provides non-invasive, computer-based vision solutions targeted at a substantial and largely un-addressed market of people who have lost their sight as a result of stroke, traumatic brain injury (TBI) or other neurological brain damage. NovaVision has a family of therapies that both restore lost vision and help to compensate for lost vision and which complement each other to maximize patient benefit. NovaVision’s therapies are clinically supported by decades of scientific research.

While other rehabilitation modalities such as speech, physical and occupational therapy have been considered a standard of care for stroke and TBI, lost vision has been largely unaddressed. NovaVision’s Visual Restoration Therapy (VRT) is designed to increase the sensitivity within the blind areas. NovaVision’s NeuroEyeCoach therapy is a compensation technique based on several decades of scientific research. It is designed to re-train patients to direct their gaze towards the affected area, bringing previously undetected objects into sight. NovaVision has operations in the US, Germany and UK. Learn more at www.NovaVision.com

Arash Sahraie, Ph.D.

Byline BIO: Dr. Arash Sahraie is Professor and Chair in Vision Sciences at the University of Aberdeen (UK) and Chief Scientific Officer (CSO) for NovaVision, which provides clinically-supported therapies for the rehabilitation of visual impairments caused by stroke or other brain injury. Learn more at www.NovaVision.com

Broadcast BIO: Our guest today is one of the top medical researchers working to restore sight to those who have suffered vision impairments as a result of neurological brain damage. Dr. Sahraie is Professor and Chair in Vision Sciences at the University of Aberdeen and Chief Scientific Officer for NovaVision. The company is a leader in the field of vision rehabilitation, has the only FDA-cleared therapy available today to restore vision loss due to neurological damage and provides a complementary compensation therapy which makes the most of remaining vision. Welcome, Professor Sahraie. What are these therapies and how do they work?

Full BIO: Arash Sahraie, Ph.D., is Professor and Chair in Vision Sciences at the University of Aberdeen (UK) and Chief Scientific Officer (CSO) for NovaVision, developer of the first FDA-cleared therapy proven to restore lost vision for people suffering from vision loss due to stroke and TBI. Considered one of the leading scientific thinkers regarding visual field deficits and restitution techniques, he has published extensively in some of the field’s most prestigious journals and lectured extensively on these topics. Dr. Sahraie is a leader in investigation of the limits and mechanisms for residual visual functions after brain injury, including the phenomenon referred to as “blindsight.” He obtained his PhD on application of physiological responses in the study of residual visual functions after brain injury in 1993, being jointly supervised by Professor John Barbur (City University, London) and Professor Larry Weiskrantz (Oxford University). His postdoctoral fellowship at the University of Oxford and City University, London, was centered on investigation of visual function after brain injury and retinal neuropathy using psychophysical and neuroimaging techniques. Professor Sahraie was appointed as a Lecturer in Aberdeen in 1998, Senior Lecturer in Psychology in 2003, Reader in Visual Neuroscience in 2005 and Chair in Vision Sciences in 2008. His research has been centered on developing non-invasive techniques for the assessment of visual function and rehabilitation of visual deficits after brain injury. His research findings have led to highly cited scientific papers as well as granted patents and commercial products. Learn more at www.NovaVision.com

Jose Romano, M.D.

Byline BIO: Jose Romano, M.D., is Chief of Stroke Division and Professor of Clinical Neurology at the University of Miami Miller School of Medicine. Dr. Romano serves on the Scientific Advisory Board for NovaVision, which provides clinically-supported therapies for the rehabilitation of visual impairments caused by stroke or other brain injury. Learn more at www.NovaVision.com

Broadcast BIO: Our guest today is a recognized leader in the different restorative approaches to vision loss caused by stroke and TBI. Dr. Jose Romano is Chief of Stroke Division and Professor of Clinical Neurology at the University of Miami Miller School of Medicine and serves on the Scientific Advisory Board for NovaVision. The company is a leader in the field of vision rehabilitation, has the only FDA-cleared therapy available today to restore vision loss due to neurological damage, and provides a complementary compensation therapy which makes the most of remaining vision. Welcome, Dr. Romano. You have had extensive clinical and research experience in different treatments of vision loss caused by stroke; can you tell us about vision loss from stroke and what should patients do?

Full BIO: Jose Romano, M.D., is Chief of Stroke Division and Professor of Clinical Neurology at the University of Miami Miller School of Medicine. Dr. Romano serves on the Scientific Advisory Board for NovaVision, developer of the first FDA-cleared therapy proven to restore lost vision for people suffering from vision loss due to stroke and TBI. For over two decades he has been focused on stroke recovery, participated in research and published on restorative approaches to homonymous hemianopsia. He has extensive experience with the restoration of vision following stroke. In 2011, Dr. Romano was awarded the Cor Vitae Stroke Award, honoring physicians who advance the treatment and prevention of stroke. He has had significant first hand clinical and research experience in the different restorative approaches to vision loss caused by stroke and TBI. Dr. Romano is a practicing physician, Professor of Clinical Neurology, Director of the Cerebrovascular (Stroke) Division at the University of Miami Miller School of Medicine and the Director of the Stroke Program at Jackson Memorial Hospital in Miami, Florida. Learn more at www.NovaVision.com

Alvaro Pascual-Leone, M.D., Ph.D.

Byline BIO: Alvaro Pascual-Leone, M.D., Ph.D., serves as Professor of Neurology and Associate Dean for Clinical and Translational Research at Harvard Medical School and Director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center. He serves on the Scientific Advisory Board for NovaVision, which provides clinically-supported therapies for the rehabilitation of visual impairments caused by stroke or other brain injury. Learn more at www.NovaVision.com

Broadcast BIO: Our guest today is a world leader in neuroplasticity including its implications for the restoration of vision. Dr. Alvaro Pascual-Leone (SAY Al-var-O Pas-quel Lee-O-nee) serves as Professor of Neurology at Harvard Medical School and Director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center. He also serves on the Scientific Advisory Board for NovaVision. The company is a leader in the field of vision rehabilitation, has the only FDA-cleared therapy available today to restore vision loss due to neurological damage, and provides a complementary compensation therapy which makes the most of remaining vision. Welcome, Dr. Pascual-Leone. What is neuroplasticity and how does it impact a patient’s potential recovery from vision loss as a result of a stroke or TBI?

Full BIO: Alvaro Pascual-Leone M.D., Ph.D., is a Professor of Neurology at Harvard Medical School and Director of Research at the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center. He serves on the Scientific Advisory Board for NovaVision, developer of the first FDA-cleared therapy proven to restore lost vision for people suffering from vision loss due to stroke and traumatic brain injury. Dr. Pascual-Leone is a world leader in neuroplasticity and its implications for the restoration of vision. A native of Spain, he received his M.D. in 1984 and his Ph.D. in Neurophysiology in 1985, both from Albert-Ludwigs University in Freiburg, Germany. He was a former Medical Fellow at the National Institute of Health. He has authored more than 450 scientific papers as well as books and holds many patents in the field of neurology, neuroscience, and neurophysiology. Dr. Pascual-Leone is a world leader in research and development, clinical application and the teaching of noninvasive brain stimulation. His research aims at understanding the mechanisms that control brain plasticity across the life span to be able to modify them for a patient’s optimal behavioral outcome. Dr. Pascual-Leone is an ardent believer in the ability to rehabilitate patients who have suffered from neurological brain damage and has done extensive work on the rehabilitation of visual field deficits resulting from brain damage such as that caused by a stroke. He is Professor of Neurology at Harvard Medical School; Director of the Berenson-Allen Center for Noninvasive Brain Stimulation; Program Director of the Harvard-Thorndike Clinical Research Unit; and an Attending Neurologist at Beth Israel Deaconess Medical Center. He is a practicing behavioral neurologist and movement disorders specialist. Learn more at www.NovaVision.com

Joseph Zihl, Ph.D.

Byline BIO: Joseph Zihl, Ph.D., is Professor of Neuropsychology at the Department of Psychology, University of Munich (Germany) and Head of the Neuropsychology Research Group at the Max Planck Institute of Psychiatry. Dr. Zihl serves on the Scientific Advisory Board for NovaVision, which provides clinically-supported therapies for the rehabilitation of visual impairments caused by stroke or other brain injury. Learn more at www.NovaVision.com

Broadcast BIO: Our guest today has a long standing interest in the rehabilitation of visual disorders in subjects with acquired brain injury and is recognized as one of the world’s experts in saccadic (or compensation) training. Joseph Zihl, Ph.D., is Professor of Neuropsychology at the Department of Psychology, University of Munich (Germany) and Head of the Neuropsychology Research Group at the Max Planck Institute of Psychiatry. Dr. Zihl serves on the Scientific Advisory Board for NovaVision. The company is a leader in the field of vision rehabilitation, has the only FDA-cleared therapy available today to restore vision loss due to neurological damage, and provides a complementary compensation therapy which makes the most of remaining vision. Welcome, Dr. Zihl. You have recently been working with NovaVision in the development of NeuroEyeCoach; can you please tell us about the therapy, the science behind it and its clinical efficacy?

Full BIO: Joseph Zihl, Ph.D., has served since 1995 as Professor of Neuropsychology at the Department of Psychology, University of Munich (Germany) and Head of the Neuropsychology Research Group at the Max Planck Institute of Psychiatry. Dr. Zihl serves on the Scientific Advisory Board for NovaVision, developer of the first FDA-cleared therapy proven to restore lost vision for people suffering from vision loss due to traumatic brain injury and stroke. Professor Zihl is a world leader in compensatory techniques for the treatment of patients who have suffered vision loss as a result of neurological brain damage. He has a longstanding interest in the rehabilitation of visual disorders in subjects with acquired brain injury and is recognized as one of the world’s experts in saccadic training. Professor Zihl received his Ph.D. in Psychology from The University of Innsbruck (Austria). He held a Post- doctoral Fellowship at the Max Planck Institute of Psychiatry in Munich from 1975-1977, where he became a senior researcher. Learn more at www.NovaVision.com

Richard H. Legge, M.D.

Byline BIO: Dr. Richard H. Legge is Assistant Professor of Ophthalmology and Visual Sciences at the University of Nebraska Medical Center in Omaha who has used NovaVision Vision Restoration Therapy (VRT) in his practice. NovaVision provides clinically-supported therapies for the rehabilitation of visual impairments caused by stroke or other brain injury. Learn more at www.NovaVision.com

Broadcast BIO: [removed per dr. legge's staff request]

Full BIO:
Dr. Richard H. Legge is Assistant Professor of Ophthalmology and Visual Sciences at the University of Nebraska Medical Center in Omaha who has used NovaVision Vision Restoration Therapy (VRT) in his practice. NovaVision provides clinically-supported therapies for the rehabilitation of visual impairments caused by stroke or other brain injury. Dr. Legge earned his M.D. at the University of Nebraska College of Medicine, completed his residency in Ophthalmology at Boston University Medical Center and his Fellowship in Neuro-Ophthalmology at Tufts University in Boston. In practice for 25 years, Dr. Legge specializes in Neuro-Ophthalmology, Pediatric Ophthalmology and Strabismus. Dr. Legge has published research and articles in periodicals such as The American Journal of Human Genetics, Ophthalmology and Neurology, and has presented at conferences on neurological and pediatric cerebral vision impairment and neuro-visual rehabilitation, including on “NovaVision Vision Restoration Therapy – An Early Experience” for the North American Neuro-Ophthalmology Society. His many professional honors include being named a “Top Ophthalmologist” by the International Association of Health Care Professionals in 2012 and being featured in the Consumers’ Research Council of America’s Guide to America’s Top Ophthalmologists 2007-2011. Learn more at www.NovaVision.com
Site Map

Powered by: www.creativform.com